Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Brookdale Senior Living (BKD) and Prothena (PRTA)

Tipranks - Tipranks - Sat Feb 21, 6:12AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Talkspace (TALK – Research Report), Brookdale Senior Living (BKD – Research Report) and Prothena (PRTA – Research Report).

President's Day Sale - 70% Off

Talkspace (TALK)

In a report released today, Bobby Brooks from Northland Securities maintained a Buy rating on Talkspace, with a price target of $7.00. The company’s shares closed last Thursday at $4.83.

According to TipRanks.com, Brooks is a 5-star analyst with an average return of 49.3% and a 73.4% success rate. Brooks covers the Industrial Goods sector, focusing on stocks such as Innovative Solutions And Support, Tetra Technologies, and Ceco Environmental. ;'>

Talkspace has an analyst consensus of Strong Buy, with a price target consensus of $6.08, representing a 33.6% upside. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $5.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Brookdale Senior Living (BKD)

In a report released yesterday, Ben Hendrix from RBC Capital reiterated a Buy rating on Brookdale Senior Living, with a price target of $17.00. The company’s shares closed last Thursday at $14.95.

According to TipRanks.com, Hendrix is a 4-star analyst with an average return of 5.2% and a 51.9% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., Ardent Health Partners, Inc., and Aveanna Healthcare Holdings. ;'>

Brookdale Senior Living has an analyst consensus of Strong Buy, with a price target consensus of $17.25, representing an 11.8% upside. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $18.00 price target.

Prothena (PRTA)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Prothena, with a price target of $12.00. The company’s shares closed last Thursday at $9.03.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.2% and a 48.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Neumora Therapeutics, Inc., and Sionna Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prothena with a $17.40 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).